Meet the Team
Our team comprises experts in pharmacokinetics and clinical pharmacology
Graham Blakey
Graham’s career has focused upon the investigation of the clinical pharmacology of new drugs and novel formulations with particular expertise in the transition of novel molecules from discovery into humans.
He is experienced in a number of PK methodologies and has used these across the drug development spectrum. Firstly for AstraZeneca, where he was a Principal Scientist and latterly in a consultative capacity. Graham is a strategic thinker and an advocate of creative and efficient clinical study design. He has applied these principles to many global drug development projects in several therapeutic areas. On many occasions Graham has contributed directly to interactions with the Regulatory Agencies. His skills have involved him in various patent cases where he has acted as an expert witness in several jurisdictions.
Graham has developed professional PK training courses for both experts and non-experts working in the pharmaceutical and bioscience sectors. Additionally, he has provided PK teaching on a number of undergraduate and postgraduate degree courses.
Graham is a pharmacist. He has an MSc in Clinical Pharmacology and a PhD from the Universities of Glasgow and Manchester respectively.
Rachael White
Rachael’s experience spans drug discovery through to clinical development with a focus in DMPK and Clinical Pharmacology. She has provided strategic and operational leadership for both pre-clinical (DMPK) and clinical pharmacology programmes. Rachael is task oriented and an accomplished project and departmental manager. In these roles she was responsible for design and interpretation, operational oversight, and delivery of projects to time, budget, and appropriate quality standards. In Bioanalysis, Rachael has been the outsourcing manager overseeing the scientific and GLP conduct of bioanalytical study phases outsourced to Contract Research Organisations (CRO).
Rachael has worked for AstraZeneca, Organon Laboratories and Sanofi as well as the CRO, Quotient Clinical. This has provided Rachael with global experience across many products, therapeutic areas, and the varied challenges of drug development.
Rachael started her scientific career at the University of Sheffield where she graduated with a BSc (Hons) in Biochemistry.
Maja Szramowska
Maja is an experienced PK scientist with an understanding of drug development from discovery through to the clinic.
Maja worked at Xenogesis and latterly at Sygnature Discovery. She is an experienced bioanalyst with expertise in method development of LC-MS assays to determine novel drug concentrations generated from pre-clinical DMPK activities. Maja is an experienced user of Phoenix WinNonlin to generate PK parameters from both pre-clinical and clinical pharmacology studies. At PharmaKinetic Maja is furthering her project management skills through acting as the point of contact for several of our clients.
Maja holds an MSci in Biochemistry from the University of Birmingham.
Mari Smith
Mari has a keen scientific curiosity and brings an attention to detail to her role as a PK Scientist.
Pharmaceutical industry experience has been gained though placements at 3M and Plasgene Ltd. In her role as a Health and Safety Co-ordinator at the University of Birmingham Mari gained proficiency implementing safe working practices across the research laboratories. Skills gained working in this regulated environment are being directly applied to the Quality Management System within PharmaKinetic, thereby ensuring the PK analyses undertaken are robust and comply with GCP principles.
Mari holds an MSci in Biochemistry from the University of Birmingham.
Rina Mistry
Rina has extensive experience in Drug Metabolism, Pharmacokinetics and Bioanalysis combined with project management and commercial experience. Rina has worked in a Pharma environment at AstraZeneca as well as in various CRO environments having previously worked for XenoGesis, Sygnature Discovery, and Charnwood Discovery.
Rina has supported pre-clinical drug development programmes and has a specialist interest in bioanalysis, and pharmacokinetics as well as experience running DMPK in vitro assays, further to this Rina has spent numerous years working in the commercial field supporting study design and contracting services. Rina is task oriented and an accomplished project and scientific study manager. She provides operational leadership for PharmaKinetic projects. In this role Rina is responsible for contract management, project management, operational oversight, and delivery of projects to time, budget, and appropriate quality standards.
Rina holds a BSc (Hons) in Biological Science (Biochemistry) from the University of Leicester.
Pete White
Pete has expertise in Drug Metabolism, Pharmacokinetics and Bioanalysis combined with extensive project management experience.
Pete has broad experience within the bioanalytical field and is a highly competent user of LC-MS, LC-MS/MS, ICP-MS, Orbitrap, QTof and Synapt G2 instrumentation. Throughout his career Pete has been responsible for the advanced method development of large and small molecules in a variety of Pharma environments. These include AstraZeneca and Organon along with several service providers such as Quotient Clinical, Xenogesis and latterly Sygnature Discovery. Pete has successfully supported drug development in the areas of pre-clinical, clinical bioanalytical and ADME. He brings a scientific and pragmatic approach to the management of bioanalytical projects.
Pete holds a BSc (Hons) in Applied Biochemical Sciences from Ulster University.
Unlock Your Project’s Potential with Our Expertise
Frequently Asked Questions
Find solutions to your most pressing queries.
Pharmacokinetics (PK) provides a quantitative assessment of a drug’s disposition around the body. Estimation of a drug’s half-life whilst associated with how long the drug stays in the body, it is also the manifestation of how the body affects the drug. In essence a reflection of the interaction between the processes that determine a drug’s fate following administration, namely, absorption, distribution, metabolism and elimination. Through understanding a drug’s PK a more realistic idea of the concentration that may be at the desired site of action is gained rather than relying on the dose given. Knowing the time-course of a drug in the body and the associated pharmacodynamic effect (therapeutic and adverse) more robust and safer dosing regimens can be found.
Contact us to find out how our training courses can provide your team with increased confidence when discussing PK within their projects.
We are a team that is passionate about pharmacokinetics (PK) and its use to aid drug development projects. Thus we provide knowledge along with the PK parameter values that we generate. Robust data output is ensured through using industry-standard analysis software and employment of a rigorous quality management system. Furthermore, we believe that good communication leads to better outcomes. All our clients benefit from a named PharmaKinetic point of contact.
Contact us to see how we can benefit your project.
Surprisingly, this does not fall into the category of ‘How long is a piece of string?’ Typically, the non-compartmental analysis undertaken at the end of a study for final reporting, in the clinical study report, takes 5 working days. Turnaround time for pharmacokinetic analysis and reporting to aid dose selection during safety review meetings in, for example, first-in-human studies would take 3 working days. For all these scenarios there are some caveats, we need sufficient notice to schedule the work. Furthermore, the number of subjects and study complexity may lengthen these standard timelines.
Contact us to discuss how we can analyse your data in a timely manner.